Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A office building designed by Frank or. Jerry on the Novartis headquarters AG in Basel, Switzerland.
Bloomberg Gety pictures
Swiss pharmaceutical giant Novartis On Friday, I mentioned better sales than expected in the fourth quarter, but less than its instructions throughout the entire year.
The fourth quarter sales increased by 16 % on the basis of a fixed currency to $ 13.2 billion, compared to $ 12.795 billion, estimated by analysts in the LSEG survey.
The basic operating income, the semester, reached $ 4.86 billion, for $ 4.23 billion.
For 2024, net sales increased by 12 % on the basis of a fixed currency to 50.32 billion dollars, compared to $ 50.47 billion. The basic operating income for the entire year increased by 22 % to $ 19.5 billion, compared to $ 17.02 billion expected.
Novartis raised its profits for the year 2024 for the third quarter in a row in October, saying that it expects net sales per year and entered the basic operation of both centenary “teenagers” versus “Mediterranean teenagers to the two highs” in the past.
CEO, Fes Narayimhan, said the results were a positive early signal since the implementation of the company’s strategic reform in 2023.
“In our full year as an innovative pharmaceutical company to play pure, Novartis presented one of the most powerful financial offers in our history, increasing its sales by 12 % of currencies (fixed currencies) and the basic operation entered 22 % cubic. The results are accompanied.
He said, “With the momentum we see at work, we expect strong sales growth with the expansion of the margin in 2025 and we remain on the right track to provide our guidance in the middle of the period.”
Looking at the future, Narasimhan said that the company focuses on the progress of the development pipeline, including more than 30 assets “with the possibility of leading distinct growth in the long term.”
This is an urgent news story and will be updated soon.
